Highlights
Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.
- Cancer of the Pancreas
- Hereditary Predisposition to Pancreatic Cancer: Whom and How To Screen and What to Look For?
- Management of Premalignant Pancreatic Lesions
- Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC
- Cases With Panel Discussion: Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer
- New Treatment Options in Pancreatic Cancer (not on IO)
- Are We Making Progress in Targeting the Microenvironment and Immune System in PDAC?
- ESMO Vesalius Talk: How to find Local and International Mentors to Build Your Career in GI Oncology
- Bile Duct Cancer
- Surgical Resection of Klatskin Tumors and Gall Bladder
- Cases With Panel Discussion: Locally Advanced Biliary Tract Cancer
- New Agents in Bile Duct Cancer
- Cases With Panel Discussion: NGS as the First-line Treatment in All Patients With Advanced Bile Duct Cancer
- ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)
- GI Cancer in Elderly: Challenges and Prospects
- Multidisciplinary Case Discussion on Oligometastatic GI Cancer
- Meet the Experts: Challenging Cases in Advanced HCC
- Esophageal and Gastric Cancers
- Endoscopic Management of Early Esophageal and Gastric Cancer
- GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT)
- Challenges with PDL Testing in Upper GI Cancer
- Checkpoint Inhibition in Esophageal Cancer
- Checkpoint Inhibition in Gastric Cancer
- New Targets and Agents in Upper GI Cancer (other than HER2)
- Hepatocellular Carcinoma
- Pathogenesis and Pathology of HCC
- Diagnostic and Imaging Challenges in HCC
- Cases With Panel Discussion: Management Strategy in HCC
- ESMO Lounge Session: Gender Medicine: Time to Address the Topic in GI Tumors
- How to Integrate and Sequence New Agents in HCC?
- Challenges and Indications for Locoregional Treatment in HCC
- WCGIC Colloqium 1: Artificial Intelligence in GI Oncology
- WCGIC Colloquium 2: Molecular Marker Platforms
- WCGIC Colloquium 3: NET tumors
- Minisymposium: The Role of Functional Imaging in GI Cancer
- Minisymposium: Special Topics in Young Adults with Cancer
- Meet the Experts: Customized Dosing for Kinase Inhibitors
- Keynote Lectures
- New Mechanistic Opportunities for Antibodies
- Targeting the HER-2 Pathway in GI Cancer
- Rectal Cancer
- MRI: New Data and Learnings in Rectal Cancer
- Debate: Is TNT standard of Care in Rectal Cancer?
- Flashes
- Surveillance in Watch & Wait Strategy: How?
- CPI in MSI-H Locally Advanced Rectal Cancer
- Cases With Panel Discussion: RAPIDO & PRODIGE strategy
- Cases With Panel Discussion: Oligometastatic Rectal Cancer
- Adjuvant Colon Cancer
- Is it Time for Personalized Adjuvant Treatment of Colon Cancer? Duration of Adjuvant Treatment
- Is it Time for Personalized Adjuvant Treatment of Colon Cancer? CtDNA-Based Decisions
- Immunoscore: A Tool for Escalation/De-escalation of Adjuvant treatment
- ESMO Lounge Session: Disparities in Access to New Drugs: How to Tackle the Reality?
- Immune Mechanisms and Microbiome
- Understanding Immune Mechanisms and Novel Targets
- Microbiome and Colorectal Cancer
- Predicting and Managing Rare Toxicities in GI Cancer Patients
- Women for Oncology: The Construction of the Majority Minority
- Surgical Advances in GI Oncology: Transplantation and Robotics
- Primary Liver Tumors
- Liver Metastases in Colorectal Cancer
- Robotic Surgery for Liver Tumors
- Colorectal Cancer: Metastatic Disease
- Algorithms in First-Line and Second-Line Metastatic Disease
- Treatment Algorithms After Second-Line Metastatic Disease
- Checkpoint Inhibitors in MSI-H Colorectal Cancer
- How to Make MSS Tumors More Sensitive for Immunotherapy
- BRAF Mutant Tumors: Strategy and New Data
- Rare Genomic Alterations Including Mutations and Fusions and Discussant
- Rare GI Tumors – NETs, GISTs, and Anal Cancer
- PRRT in NET
- GIST: Molecular Analysis and New Agents
- Anal Cancer: Role of IOs